Pancreatic Cancer Research

ResearcherGunma UniversityActive in the last 2 years

Kenichiro Araki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5438-4551; OpenAlex author ID A5010977265. Sources: OpenAlex.

Their work

Papers
19 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 19

  1. Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon-Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement. Co-author DOI 10.1002/ags3.70259↗
  2. Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of… First author DOI 10.1002/ags3.70270↗
  3. CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T-Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcin… First author DOI 10.1002/ags3.70275↗
  4. Impact of Preoperative Weight Loss on Prognosis in Patients with Pancreatic Cancer. First author DOI 10.3390/biomedicines13071703↗
  5. Pancreatic cancer and sarcopenia: a narrative review of the current status. First author DOI 10.1007/s10147-024-02576-2↗
  6. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. First author DOI 10.1111/cas.16087↗
  7. Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12671↗
  8. High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s10147-023-02342-w↗
  9. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… Co-author DOI 10.1007/s10147-023-02399-7↗
  10. Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World St… Co-author DOI 10.1159/000525742↗
  11. D-Dimer Could Be a Surrogate Postoperative Prognostic Marker of Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001537↗
  12. Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report. Co-author DOI 10.1186/s40792-020-01029-y↗
  13. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreati… Co-author DOI 10.1245/s10434-019-07708-x↗
  14. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. First author DOI 10.1111/cas.13847↗
  15. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-017-3477-4↗
  16. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12307↗
  17. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. First author DOI 10.18632/oncotarget.14703↗
  18. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. First author DOI 10.18632/oncotarget.22634↗
  19. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Co-author DOI 10.1002/ijc.25946↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ken Shirabe · 17 shared papers, 2017–2026 · strength 2.71
  2. Mariko Tsukagoshi · 14 shared papers, 2017–2026 · strength 2.41
  3. Takamichi Igarashi · 10 shared papers, 2017–2026 · strength 1.54
  4. Kei Hagiwara · 10 shared papers, 2018–2026 · strength 1.47
  5. Norihiro Ishii · 11 shared papers, 2017–2026 · strength 1.36
  6. Akira Watanabe Watanabe · 11 shared papers, 2017–2024 · strength 1.14
  7. Takehiko Yokobori · 9 shared papers, 2017–2026 · strength 1.03
  8. Norifumi Harimoto · 8 shared papers, 2018–2024 · strength 0.95
  9. Takahiro Yamanaka · 8 shared papers, 2017–2024 · strength 0.78
  10. Ryosuke Fukushima · 2 shared papers, 2025–2026 · strength 0.52
  11. Takaomi Seki · 2 shared papers, 2025–2026 · strength 0.51
  12. Hiroyuki Kuwano · 6 shared papers, 2011–2019 · strength 0.36
  13. Tatsuya Ohno · 1 shared paper, 2026 · strength 0.29
  14. Masahiko Okamoto · 1 shared paper, 2026 · strength 0.29
  15. Atsushi Masamune · 2 shared papers, 2019–2024 · strength 0.26
  16. Bolag Altan · 3 shared papers, 2017–2018 · strength 0.19
  17. Kiyoaki Ito · 1 shared paper, 2024 · strength 0.18
  18. Tohru Utsunomiya · 1 shared paper, 2023 · strength 0.15
  19. Chingunjav Batbayar · 1 shared paper, 2023 · strength 0.15
  20. Mototsugu Shimokawa · 1 shared paper, 2023 · strength 0.15
  21. Keishi Sugimachi · 1 shared paper, 2023 · strength 0.15
  22. Hiromitsu Hayashi · 1 shared paper, 2023 · strength 0.15
  23. Hideo Baba · 1 shared paper, 2023 · strength 0.15
  24. Tomoharu Yoshizumi · 1 shared paper, 2023 · strength 0.15
  25. Tadashi Uwagawa · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.